Last reviewed · How we verify
Imitrex and two Aleve
Imitrex and two Aleve is a Small molecule drug developed by Stephen H. Landy, M.D.. It is currently FDA-approved.
Imitrex is a medication used to treat migraine, as indicated by ClinicalTrials.gov. Aleve, also known as naproxen, is a nonsteroidal anti-inflammatory drug (NSAID) that has been studied in combination with Imitrex for migraine treatment, but its primary use is for relieving pain, inflammation, and fever.
At a glance
| Generic name | Imitrex and two Aleve |
|---|---|
| Sponsor | Stephen H. Landy, M.D. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treximet Early Intervention Adolescent Migraine (PHASE2, PHASE3)
- Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Imitrex (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imitrex and two Aleve CI brief — competitive landscape report
- Imitrex and two Aleve updates RSS · CI watch RSS
- Stephen H. Landy, M.D. portfolio CI
Frequently asked questions about Imitrex and two Aleve
What is Imitrex and two Aleve?
Who makes Imitrex and two Aleve?
What development phase is Imitrex and two Aleve in?
Related
- Manufacturer: Stephen H. Landy, M.D. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing